About Us

Company Overview

TheraSource is a growing biotech company founded in 2004 and located in the Greater New York area. Our mission is to develop novel anti-inflammatory therapeutics for the treatment of human diseases. Our founder and scientists have demonstrated the efficacy of several newly-discovered molecules in preclinical studies of various medical conditions including ischemic acute kidney injury (AKI), inflammatory bowel disease (IBD), acute ischemic stroke, acute radiation syndrome, shock and sepsis, leading to >250 peer-reviewed publications.

TheraSource's R&D unit resides in The Feinstein Institute for Medical Research which is equipped with a state-of-the-art preclinical testing facility. Our research team currently consists of 9 scientists with MD or PhD degrees in multidisciplinary areas, including protein chemistry, cell biology, immunology, pathophysiology, and clinical medicine. Since its founding, TheraSource has raised >$12 million from industry and government entities, and received over 10 Small Business Innovation Research (SBIR) awards from the National Institutes of Health (NIH). The company possesses 14 utility patents covering 5 molecules to treat various inflammatory human diseases.

 
 

Leadership

Ping Wang, MD, President
Dr. Wang has more than 25 years of experience as an investigator in the fields of surgery and critical care, and his research has been consistently supported by the NIH (via R01 mechanism) since 1995. Dr. Wang is Chief Scientific Officer (CSO) of the Feinstein Institute for Medical Research (FIMR), and President-Elect and President of the Shock Society. He has served as Council Member for the Shock Society and the Surgical Infection Society, and as a member of various NIH study sections. He has also served as Program Chair for Shock Society’s annual meeting in 2013. He has been on editorial boards of 10 scientific journals. He has been a faculty member at various medical schools in the US. He is the author of more than 340 peer-reviewed publications, editor of a book, and an inventor of 14 patents. Dr. Wang received his MD and trained as a surgeon in China, and received his postdoctoral training at the University of Washington, WA. Dr. Wang is the Founder and has served as CEO of TheraSource.

Weng-Lang Yang, PhD, Chief Scientific Officer (CSO)
Dr. Yang has extensive and significant knowledge in biochemistry, enzymology, cell biology, and molecular biology, and experience in protein purification and characterization. He has developed several experimental models to study surgical technologies for tumor eradication. He also participated in designing a Phase II clinical trial. Dr. Yang has been a faculty member at various medical schools in the US. He has co-authored 69 peer-reviewed publications, including one in Nature Medicine. Dr. Yang received BS from Fu Jen Catholic University in Taiwan, PhD from Rutgers University, NJ, and postdoctoral training at the Cancer Institute of New Jersey.

Mian Zhou, MD, Vice President (VP), Operations
Dr. Zhou has been trained in pathology and is a certified histologist by American Society of Clinical Pathologists. She has more than 20 years of research experience in studying critical care-related medical conditions. She is a co-founder of TheraSource. In addition to her active role in research and development, she has extensive experience in fund account management, supply and equipment acquisition, and logistic support for corporate operations. Dr. Zhou received her biology and medical education in China.

Max Brenner, MD PhD, Director of Drug Discovery
Dr. Brenner is a trained rheumatologist with extensive experience in molecular medicine, biomarkers, drug development, and animal models of human disease. As a clinician-scientist, he has over ten years of experience in the identification of novel molecular targets and development of novel therapeutic agents for autoimmune and inflammatory diseases. Dr. Brenner received his MD in Brazil, a PhD from the Elmezzi Graduate School of Molecular Medicine, and postdoctoral training at The Feinstein Institute for Medical Research, both in NY.

Wayne Chaung, PhD, Director of Drug Development
Dr. Chaung has more than 15-years of industrial experience, and previously worked at Hoffmann-LaRoche Inc. He is a co-inventor in 4 patents on subcellular organelle purification systems. He has strong background and training in microbiology and molecular biology, and expertise in developing the production of recombinant proteins. Dr. Chaung received a BS from the National Taiwan University, a PhD from Clemson University, SC, and postdoctoral training at the New York University Medical Center.

Fangming Zhang, MD PhD, Team Leader of Preclinical Development
Dr. Zhang has more than 30 years of research experience. She has strong background and training in physiology, immunology, inflammation, and preclinical models of acute kidney injury, shock, trauma, and hemorrhage. Dr. Zhang received her MD from Guiyang Medical College and a PhD from the Third Medical University, both in China, and postdoctoral training at Yale University School of Medicine.